JP2011503193A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503193A5
JP2011503193A5 JP2010534149A JP2010534149A JP2011503193A5 JP 2011503193 A5 JP2011503193 A5 JP 2011503193A5 JP 2010534149 A JP2010534149 A JP 2010534149A JP 2010534149 A JP2010534149 A JP 2010534149A JP 2011503193 A5 JP2011503193 A5 JP 2011503193A5
Authority
JP
Japan
Prior art keywords
alkylene
substituted
unsubstituted
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/083262 external-priority patent/WO2009064802A2/en
Publication of JP2011503193A publication Critical patent/JP2011503193A/ja
Publication of JP2011503193A5 publication Critical patent/JP2011503193A5/ja
Pending legal-status Critical Current

Links

JP2010534149A 2007-11-13 2008-11-12 ヒトホスファチジルイノシトール３−キナーゼδの阻害剤 Pending JP2011503193A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98772307P 2007-11-13 2007-11-13
PCT/US2008/083262 WO2009064802A2 (en) 2007-11-13 2008-11-12 Inhibitors of human phosphatidyl-inositol 3-kinase delta

Publications (2)

Publication Number Publication Date
JP2011503193A JP2011503193A (ja) 2011-01-27
JP2011503193A5 true JP2011503193A5 (https=) 2012-12-20

Family

ID=40639422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534149A Pending JP2011503193A (ja) 2007-11-13 2008-11-12 ヒトホスファチジルイノシトール３−キナーゼδの阻害剤

Country Status (13)

Country Link
US (1) US20110021541A1 (https=)
EP (1) EP2220089A4 (https=)
JP (1) JP2011503193A (https=)
KR (1) KR20100119745A (https=)
CN (1) CN101952292A (https=)
AU (1) AU2008321099A1 (https=)
CA (1) CA2716334A1 (https=)
EA (1) EA201070611A1 (https=)
GE (1) GEP20125635B (https=)
IL (1) IL205747A0 (https=)
NZ (1) NZ585460A (https=)
SG (1) SG185996A1 (https=)
WO (1) WO2009064802A2 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
JP2013545749A (ja) * 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
MX2014000648A (es) * 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
CN102614177B (zh) * 2012-03-06 2014-08-06 北京伟峰益民科技有限公司 卢帕他定在制备治疗慢性阻塞性肺病药物组合物中的应用
KR20140138293A (ko) 2012-03-16 2014-12-03 액시킨 파마수티컬스 인코포레이티드 3,5-다이아미노피라졸 키나아제 억제제
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN104768952B (zh) * 2012-08-08 2016-10-19 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MX2017000208A (es) 2014-07-04 2017-05-01 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
CN107033145B (zh) * 2016-02-04 2019-11-22 浙江大学 苯并噻嗪和苯并噻二嗪类化合物及制备和应用
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
EP4106821A1 (en) * 2020-02-19 2022-12-28 Friedrich Miescher Institute for Biomedical Research Novel therapeutical tools and methods using temperature-senstive receptors for treating blindness
WO2026055444A1 (en) * 2024-09-06 2026-03-12 Ventus Therapeutics U.S., Inc. Caspase-4 inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782137A (en) * 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5858753A (en) * 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2788383T3 (es) * 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
MXPA03005152A (es) * 2000-12-11 2004-10-14 Tularik Inc Antogonista de cxcr3.
US6518227B2 (en) * 2001-02-13 2003-02-11 Robert Woosley Solvent composition for denture adhesive
US7262187B2 (en) * 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
AU2002363960B2 (en) * 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
SI2612862T1 (sl) * 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
CN101027309B (zh) * 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
US20090298856A1 (en) * 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
CA2612585A1 (en) * 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
US20090291955A1 (en) * 2005-11-15 2009-11-26 Crane Sheldon N Azacyclohexane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
DE602007006947D1 (de) * 2006-05-23 2010-07-15 Hoffmann La Roche Pyridopyrimidinonderivate
KR20090087027A (ko) * 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
WO2008118454A2 (en) * 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer

Similar Documents

Publication Publication Date Title
JP2011503193A5 (https=)
RU2308455C2 (ru) Аминопиримидины и пиридины
CA2716334A1 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
Arulaabaranam et al. Computational assessment on wave function (ELF, LOL) analysis, molecular confirmation and molecular docking explores on 2-(5-Amino-2-Methylanilino)-4-(3-pyridyl) pyrimidine
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
JP2021529812A5 (https=)
JP2009532475A5 (https=)
SI2961736T1 (en) Histone demethylase inhibitors
JP2012508252A5 (https=)
RU2011151085A (ru) Азаиндолы, полезные в качестве ингибиторов янус-киназ
CA2446756A1 (en) Thiazole compounds useful as inhibitors of protein kinase
JP2017528524A5 (https=)
SI3009431T1 (en) 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer
JP2020506951A5 (https=)
JP2010511721A5 (https=)
US6492516B1 (en) Compounds having cytokine inhibitory activity
JP2006515858A5 (https=)
RU2005128550A (ru) Ингибиторы гистондезацетилазы из новых производных бензамида с сильной дифференцировочной и антипролиферативной активностью
RU2005111225A (ru) Производные триазаспиро[5.5]ундекана и лекарственные средства, содержащие их в качестве активного ингредиента
JP2011507854A5 (https=)
CN1295566A (zh) 用于治疗hiv感染的三取代1,3,5－三嗪衍生物
RU2004126671A (ru) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2020507606A5 (https=)
JP2005511545A5 (https=)